Netherlands-Based Detact Diagnostics Plans Keene, New Hampshire, U.S. Headquarters
05/12/2022
The expansion is in partnership with the Hannah Grimes Center for Entrepreneurship, which provides resources for entrepreneurs and companies in the state’s rural Monadnock Region, and Keene State College, which will provide space for Detact Diagnostics to create a Clinical Laboratory Improvement Amendment or (CLIA)-certified laboratories as well as an expansive internship and employment program.
“With its easily accessible networking opportunities compared to larger markets, plus its life-sciences ecosystem and the support from Hannah Grimes, New Hampshire is the ideal destination for our U.S. expansion,” said Joost Gazendam, CEO of Detact Diagnostics. “From its proximity to the Manchester and Nashua areas, to its affordability, quality of life, and community connectivity, this rural region offers endless benefits that will allow us to continue to grow our company, educate a new generation of professionals and deploy life-changing technology.”
CLIA-certified laboratories are federally regulated sites that test human specimens to diagnose, prevent and treat disease. The lab space to be developed at Keene State College will be used for Detact Diagnostics’ on-site bacterial-detection platforms, which enable healthcare providers and food-processing professionals to detect the presence of virus and bacteria and allow for fast, affordable and precise treatment.
“I am happy to welcome Detact to New Hampshire’s growing life science community,” said New Hampshire Department of Business and Economic Affairs Commissioner Taylor Caswell. “In addition to the world-class technology being researched and implemented in our state, this expansion and partnership with Keene State College further demonstrates the value of our ‘triangle’ strategy (employer-academic center-government) to generate high tech investment statewide.”
The patented Detact Diagnostics platform technology called VIPER (Visualization by Infrared Peptide Reaction) involves the immediate release of a quenched Near Infrared (NIR) molecule from its peptide bond after contact with a specific bacteria/enzyme, which emits NIR-light (NIRL). The amount of light released determines the presence of bacteria or viruses. Due to its speed, precision and sensitivity, even with very diluted samples, the potential of this technology is superior compared to other testing products.
Project Announcements
Swiss-Based Hoffmann-La Roche Limited Expands Mississauga, Ontario, Canada, Operations
12/12/2024
Wrap Technologies Plans Norton, Virginia, Manufacturing-Distribution Operations
12/12/2024
C BLOX Plans Montgomery-Huntsville, Alabama, Data Center Operations
12/12/2024
EaglePicher Technologies Expands Joplin, Missouri, Manufacturing Operations
12/10/2024
France-Based Sartorius Stedim Plans Marlborough, Massachusetts, Bioprocess Operations
12/10/2024
357 Brewers Expands Myrtle Beach, South Carolina, Operations
12/05/2024
Most Read
-
How Automation Is Actually Closing the Labor Gap
Q4 2024
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
The Role of Rail in Industrial Development
Q4 2024
-
Hydrogen Industry in Canada: A Global Leader in the Clean Energy Revolution
Q3 2024
-
Which AI Tools Work for Job Recruiters?
Q3 2024
-
Permitted Power Capacity Foreshadows Health of Regional Economies
Q3 2024
-
Navigating Non-Disclosure Agreements in Site Selection
Q3 2024